Desvenlafaxine Tablet, Extended Release
Product Images NDC 68788-7175

7 FDA label images from Preferred Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68788-7175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Desvenlafaxine Extended Release Tablets 100mg

Desvenlafaxine Extended Release Tablets 100mg
Desvenlafaxine Extended-Release Tablets 100 mg, extended release oral tablets. The label states generic for Pristiq, with each film-coated tablet containing 152 mg of Desvenlafaxine Succinate equivalent to 100 mg Desvenlafaxine. The labeler is Preferred Pharmaceuticals Inc. Directions are provided in both English and Spanish. The manufacturer listed is Breckenridge Pharmaceuticals, Inc., Boca Raton, FL.*
FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

Figure 1 (Desvenlafaxine Figure1)
A pharmacokinetic chart showing geometric mean ratios with 90% confidence intervals for Cmax and AUC parameters across varying degrees of renal and hepatic impairment, as well as population groups by gender and age. The x-axis represents change relative to reference, ranging from 0.5 to 3.5.*
FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

Figure 2 (Desvenlafaxine Figure2)
A pharmacokinetic (PK) chart showing the geometric mean ratio (90% confidence interval) for Cmax and AUC changes of Desvenlafaxine when co-administered with ketoconazole, a CYP3A4 inhibitor. The horizontal axis represents change relative to reference, with values ranging from 0.5 to 2.*
FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

Figure 3 (Desvenlafaxine Figure3)
A forest plot chart illustrating the geometric mean ratio (90% confidence interval) of pharmacokinetic parameters (Cmax and AUC) for Desvenlafaxine at various doses interacting with different drugs including Desipramine, Midazolam, Tamoxifen, and Aripiprazole. The chart shows relative changes in drug exposure compared to reference values.*
FDA Label Image

Figure 4 (Desvenlafaxine Image4)

Figure 4 (Desvenlafaxine Image4)
A Kaplan-Meier curve comparing the estimated proportion of patients with relapse over time (days from randomization) for Desvenlafaxine Extended-Release Tablets 50 mg versus placebo. The x-axis shows time to relapse in days, and the y-axis shows the estimated proportion of patients with relapse as a percentage.*
FDA Label Image

Figure 5 (Desvenlafaxine Image5)

Figure 5 (Desvenlafaxine Image5)
A Kaplan-Meier curve chart showing the estimated proportion of patients with relapse over time (days from randomization) for two groups: Desvenlafaxine Extended-Release Tablets and Placebo. The x-axis represents time to relapse in days, and the y-axis shows the percentage of patients with relapse. The chart compares relapse rates between the treatment and placebo groups over approximately 180 days.*
FDA Label Image

Structure (Desvenlafaxine Structure1)

Structure (Desvenlafaxine Structure1)
Chemical structure of Desvenlafaxine Succinate depicted as a molecular diagram showing its key chemical groups and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.